|

BioNTech jab 97% effective against symptomatic cases

New study suggests Pfizer-BioNTech vaccine also prevents asymptomatic coronavirus infections

News Service
18:43 - 11/03/2021 Thursday
Update: 19:07 - 11/03/2021 Thursday
AA
Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020.
Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020.

US pharmaceutical firm Pfizer and its German biotech partner BioNTech announced Thursday that the real-world data by the Israeli Health Ministry demonstrates their vaccine’s "high effectiveness," in preventing COVID-19.

The latest analysis by the Israeli Health Ministry using the public health data between Jan. 17 and March 6 showed that the Pfizer/BioNTech vaccine was at least 97% effective at preventing asymptomatic infections two weeks after the second vaccine dose.

The analysis also found that the vaccine’s effectiveness was 94% against asymptomatic coronavirus infections.

“These findings are also important, as the data were generated at a time when the SARS-CoV-2 variant B.1.1.7 (also known as UK variant of coronavirus) was the dominant strain,” co-founder and CEO of BioNTech Ugur Sahin said in a written statement.

#BioNTech/Pfizer
#Coronavirus
#COVID-19 vaccine
#Israel's Health Ministry
#pandemic
3 years ago